Form 4: Indaptus Therapeutics Director Anthony Maddaluna Reports Stock Option Grant

Director Anthony Maddaluna reports acquisition of stock options in Indaptus Therapeutics.

Summary

• Anthony Maddaluna, a director of Indaptus Therapeutics, Inc. (INDP), reported the acquisition of stock options.
• The transaction occurred on June 6, 2024.
• Maddaluna acquired options to purchase 12,500 shares of common stock at an exercise price of $2.63 per share.
• The options vest on June 6, 2025, and expire on June 6, 2034.
• Following the transaction, Maddaluna directly owns options for 12,500 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. The grant itself can be seen as a slightly positive indicator of confidence, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech industry.
• The vesting schedule of one year is fairly standard.
• The ten year expiry is also standard.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, Form 4, Indaptus Therapeutics, director, Maddaluna, INDP, acquisition